Glenmark Pharma on Tuesday moved the Delhi High Court, seeking setting aside the National Pharmaceutical Pricing Authority’s standing order that fixed a lower retail price than the launched price of its anti-diabetic drug formulations comprising Remogliflozin + Vidagliptin + Metmformin.
Glenmark Pharmaceuticals Limited, a research-led global pharmaceutical company, has launched a fixed dose combination (FDC) of its novel, patent protected, globally researched sodium glucose co-transporter inhibitor (SGLT2i) - remogliflozin etabonate and another widely used DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor) - vildagliptin, with metformin (first-line medication for the treatment of type 2 diabetes).
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India
Amid serious global attention on Covid-19 pandemic, India's Natco PharmaNSE 7.73 % has quietly launched the generic versions of AstraZenecaNSE 12.78 %'s patented anti-diabetes brand Farxiga. Natco named its brand Dapnat, which will be available in 5mg and 10mg strengths. These products will be priced significantly lower than the two strengths of Farxiga (dapagliflozin) sold in India.
Mankind Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. today inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, has received regulatory approval to market a combination of its novel, patent protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor remogliflozin etabonate (Remogliflozin) and metformin hydrochloride (Metformin) film coated tablets in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults. Glenmark will commercialize the product under the brand names Remo-M and Remozen-M.
India’s Glenmark in April launched domestically a new SGLT2 inhibitor called Remogliflozin — marking the first-ever launch of the diabetes drug, which was partly developed by GSK $GSK. SGLT2 inhibitors, such as Forxiga, Invokana and Jardiance, work by preventing the kidneys from reabsorbing glucose back into the blood. Remogliflozin will now also be sold in combination with the decades-old metformin in India, Glenmark said on Monday.
Glenmark and Torrent licensing deal for remogliflozin etabonate in India
Glenmark Pharmaceuticals on April 30 launched a novel and patented anti-diabetes drug belonging to the class of sodium glucose co-transporter-2 (SGLT2) inhibitor, which is said to be 50-60 percent cheaper than the existing medications of same class in the market.